1
|
Dent R, André F, Gonçalves A, Martin M, Schmid P, Schütz F, Kümmel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortés J. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol 2024:S0923-7534(24)00107-8. [PMID: 38755096 DOI: 10.1016/j.annonc.2024.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2024] [Accepted: 04/05/2024] [Indexed: 05/18/2024] Open
Abstract
BACKGROUND Immune checkpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic triple-negative breast cancer (aTNBC), but randomised data in rapidly relapsing aTNBC are scarce. PATIENTS AND METHODS IMpassion132 (NCT03371017) enrolled patients with aTNBC relapsing <12 months after last chemotherapy dose (anthracycline and taxane required) or surgery for early TNBC. PD-L1 status was centrally assessed using SP142 before randomisation. Initially patients were enrolled irrespective of PD-L1 status. From August 2019, enrolment was restricted to PD-L1-positive (tumour immune cell ≥1%) aTNBC. Patients were randomised 1:1 to placebo or atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy until disease progression or unacceptable toxicity. Stratification factors were chemotherapy regimen (carboplatin plus gemcitabine or capecitabine monotherapy), visceral (lung and/or liver) metastases and (initially) PD-L1 status. The primary endpoint was overall survival (OS), tested hierarchically in patients with PD-L1-positive tumours and then, if positive, in the modified intent-to-treat (mITT) population (all-comer patients randomised pre-August 2019). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and safety. RESULTS Among 354 patients with rapidly relapsing PD-L1-positive aTNBC, 68% had a disease-free interval of <6 months and 73% received carboplatin/gemcitabine. The OS hazard ratio was 0.93 (95% confidence interval 0.73-1.20, P = 0.59; median 11.2 months with placebo versus 12.1 months with atezolizumab). mITT and subgroup results were consistent. Median PFS was 4 months across treatment arms and populations. ORRs were 28% with placebo versus 40% with atezolizumab. Adverse events (predominantly haematological) were similar between arms and as expected with atezolizumab plus carboplatin/gemcitabine or capecitabine following recent chemotherapy exposure. CONCLUSIONS OS, which is dismal in patients with TNBC relapsing within <12 months, was not improved by adding atezolizumab to chemotherapy. A biology-based definition of intrinsic resistance to immunotherapy in aTNBC is urgently needed to develop novel therapies for these patients in next-generation clinical trials.
Collapse
Affiliation(s)
- R Dent
- Division of Medical Oncology, National Cancer Center, Singapore; Duke-NUS Medical School, Singapore, Singapore.
| | - F André
- Gustave Roussy, Université Paris Saclay, Villejuif
| | - A Gonçalves
- Aix Marseille University, CNRS, INSERM, Department of Medical Oncology, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - M Martin
- Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
| | - P Schmid
- Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, UK
| | - F Schütz
- University Breast Unit, National Center for Tumor Diseases, Heidelberg
| | - S Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen; Department of Gynecology with Breast Center, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - S M Swain
- Georgetown University Medical Center and MedStar Health, Washington, USA
| | - A Bilici
- Department of Medical Oncology, Istanbul Medipol University Medical Faculty, Istanbul, Turkey
| | - D Loirat
- Medical Oncology Department, Institut Curie, Paris, France
| | | | - S-A Im
- Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul National University, Seoul
| | - Y H Park
- Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - M De Laurentis
- Department of Breast Oncology, IRCCS Istituto Nazionale Tumori Fondazione Giovanni Pascale, Napoli
| | - M Colleoni
- Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan
| | - V Guarneri
- Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, Padova; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova
| | - G Bianchini
- Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan; Università Vita-Salute San Raffaele, Milan, Italy. https://twitter.com/BianchiniGP
| | - H Li
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Z Kirchmayer Machackova
- Global Product Development/Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - J Mouta
- Global Product Development/Medical Affairs Oncology, Roche Farmacêutica Química Lda, Amadora, Portugal
| | - R Deurloo
- Translational Medicine Oncology gRED, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - X Gan
- Product Development Safety, Roche (China) Holding Ltd, Shanghai, China
| | - M Fan
- Data Science, Hoffmann-La Roche Limited, Mississauga, Canada
| | - A Mani
- Global Product Development, Genentech/Roche, South San Francisco, USA
| | - A Swat
- Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - J Cortés
- International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid; IOB Madrid, Hospital Beata Maria Ana, Madrid, Spain
| |
Collapse
|
2
|
Wang B, Chen J, Fan M. Plasma Exosomal miRNAs as Response Biomarkers of Immunotherapy in Extensive-Stage Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e70. [PMID: 37786053 DOI: 10.1016/j.ijrobp.2023.06.801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Immunotherapy combined with chemotherapy has become the first-line standard treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC). The reliable biomarkers stratifying true responders of immunotherapy effectively are unknown, and it is urgent to identify novel biomarkers in clinical. Exosomal miRNAs are considered to play a role in intercellular communication among immune cells and interaction between immune cells and tumor cells. The purpose of this study was to explore the possibility of using plasma-derived exosomal miRNAs as potential biomarkers for identifying responses to immunotherapy in ES-SCLC. MATERIALS/METHODS From March 2020 to September 2021, 24 patients with ES-SCLC who received PD-L1 inhibitors were enrolled. Tumor assessments were conducted after every two treatment cycles according to RECIST 1.1. Plasma samples of these patients were collected before administering PD-L1 inhibitors as the baseline, and after every four cycles until the occurrence of disease progression. Plasma exosomes were isolated by ultracentrifugation, then total RNA was extracted. The miRNA profile was analyzed with small RNA next-generation sequencing followed by differential expression analysis. RESULTS Of the 24 patients, 15 underwent immunotherapy maintenance after completing four cycles of PD-L1 inhibitor plus chemotherapy. In order to identify biomarkers for a better response to immunotherapy, all five responders (patients achieving PR) and four non-responders (patients achieving PD) at tumor assessment within eight cycles of the maintenance phase were included for differential expression analysis. Surprisingly, hsa-miR-320c, hsa-miR-320d, and hsa-miR-320e showed a trend of increased expression in the non-responders compared with the responders at baseline and were significantly downregulated in the post-treatment plasma exosomes compared with pre-treatment samples of the responders. CONCLUSION Exosomal miRNA profiles are discordant between responders and non-responders of anti-PD-L1 treatment. Hsa-miR-320c, hsa-miR-320d, and hsa-miR-320e were identified as potential biomarkers for predicting the efficacy of immunotherapy in patients with ES-SCLC.
Collapse
Affiliation(s)
- B Wang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - J Chen
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - M Fan
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| |
Collapse
|
3
|
Chen J, Wang B, Fan M. Stereotactic Radiotherapy (SRT) in Combination with Aumolertinib to Treat Intracranial Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Update of a Phase II, Prospective Study. Int J Radiat Oncol Biol Phys 2023; 117:e94. [PMID: 37786220 DOI: 10.1016/j.ijrobp.2023.06.855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Stereotactic radiotherapy (SRT) is highly effective and less toxic for limited intracranial metastases. Aumolertinib is a tolerable third-generation epidermal growth factor receptor tyrosine kinase inhibitor that has CNS efficacy in patients with EGFR-mutant NSCLC. We aim to investigate the efficacy and safety of aumolertinib followed by SRT in patients with intracranial oligometastatic NSCLC. MATERIALS/METHODS Intracranial oligometastatic Patients with EGFR sensitive mutations (EGFR-TKIs naive) were enrolled and received aumolertinib 110mg daily until intracranial disease progression. Then SRT (32-40 Gy total, 8 Gy/f) was given to intracranial oligo-progression disease if possible. The primary endpoint was intracranial objective response rate (iORR). Secondary endpoints included intracranial progression-free survival (iPFS), intracranial duration of response (iDOR)according to RECIST 1.1, cerebral radiation necrosis rate (CRNR) and overall survival (OS). Safety was evaluated according to Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). This trial is registered with ClinicalTrials.gov, NCT04519983. RESULTS To February 10, 2023, a total of 38 patients were enrolled and 35 patients were assessable followed for 3 months to 18 months. All patients received 110mg aumolertinib daily and received at least one independent imaging evaluation by a radiologist. After oral administration of aumolertinib, the best response of 94% patients in intracranial and extracranial lesions was partial response (PR). Two patients had stable intracranial disease. At data cut-off, one patient developed intracranial primary lesion progression at 12 months after oral administration of aumolertinib but stable in extracranial lesions. SRT treatment was given to this patient. No grade ≥3 adverse events occurred after continued oral administration of aumolertinib. The most common adverse reactions were rash and abnormal liver enzymes, 1 patient had grade 2 CK elevation. CONCLUSION This report showed pronounced intracranial objective response benefit in patients with intracranial oligometastatic disease followed by SRT after intracranial oligo-progression and no new safety signals. Aumolertinib has promising efficacy and good tolerability in intracranial oligometastatic EGFR mutated NSCLC. [Keywords] Non-small cell lung cancer; epidermal growth factor receptor tyrosine kinase inhibitor; Aumolertinib; Stereotactic radiotherapy.
Collapse
Affiliation(s)
- J Chen
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - B Wang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - M Fan
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| |
Collapse
|
4
|
Feng M, Tang Y, Fan M, Li L, Wang S, Yin Q, Ai H, Zhao S, Yin Y, Liu D, Ren Y, Li J, Li F, Lang J. Low-Dose Fractionated Radiotherapy Combined with Neoadjuvant Chemotherapy for T3-4 Nasopharyngeal Carcinoma Patients: The Preliminary Results of a Phase II Randomized Controlled Trial. Int J Radiat Oncol Biol Phys 2023; 117:e580-e581. [PMID: 37785764 DOI: 10.1016/j.ijrobp.2023.06.1921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Over 70% of NPC patients were local advanced NPC (LANPC). The 5-year local recurrence-free survival rate is only 70% in T3-4 patients. Neoadjuvant chemotherapy (NACT) followed with concurrent chemoradiotherapy (CCRT) was recommended for LANPC patients. Low-dose fractionated radiotherapy (LDFRT), which is <100cGy, induces enhanced cell killing by the hyper-radiation sensitivity phenomenon and potentiates effects of chemotherapy. The synergy of LDFRT and NACT has not been used in the clinical practice and few studies focused on it. A single arm study found the ORR of primary site was improved to 90% for head and neck squamous carcinoma patients treated with LDFRT and NACT. Our previous study found the ORR of lymph nodes was higher in LDFRT group for high-risk LANPC patients. However, another study showed there was no significant difference between LDFRT and control group for LANPC patients. So, we aimed to investigate the potential efficacy of this novel neoadjuvant therapy for T3-4 NPC patients. MATERIALS/METHODS A total of 60 pathological confirmed T3-4 (UICC/AJCC8th) NPC patients were prospectively enrolled in our study. They were randomly assigned to two groups. For the LDFRT group, the patients received 3 cycles of NACT (docetaxel 75mg/m2 D1, cisplatin 80mg/m2 D1) with LDFRT, and followed with CCRT. LDFRT was delivered as 50cGy per fraction twice a day to primary site on D1,2 for each cycle of NACT. The patients in the control group only received NACT and followed with CCRT. All the patients underwent IGRT. RECIST criteria and CTCAE 5.0 was used to evaluate the ORR and toxicity at post-NACT and the completion of CCRT. RESULTS From February 2022 to December 2022, 60 T3-4 NPC patients were included, and 30 patients for each group. For the primary site, the median volume reduction rate and the ORR after NACT was significantly improved in LDFRT group (69.27% vs 40.10%, p<0.001;93.33% vs 73.33%, p = 0.038). For the median volume reduction rate of primary site and lymph node, it was also obviously improved in LDFRT group (86.59% vs 55.43%, p<0.001). Though there was a tendency of ORR improvement in LDFRT group, but no significant difference (96.67% vs 83.33%, p = 0.195). After the completion of CCRT, the median volume reduction rate of primary site had an increased tendency in LDFRT group (96.16% vs 88.3%, p = 0.065), but the ORR had no statistical significance (LDFRT group: CR 45.8%, PR 54.2%; control group: CR 37.5%, PR 62.5%). For the toxicity, the incidence of grade 3-4 adverse events had no difference between two groups (p = 0.786). No grade 5 adverse events occurred. CONCLUSION LDFRT combined with NACT could obviously improve the median volume reduction rate and ORR of primary tumor for T3-4 NPC patients, and the toxicity was similar and tolerable. This novel treatment could be a promising strategy to improve treatment response and needed to be confirmed further.
Collapse
Affiliation(s)
- M Feng
- Sichuan Cancer Hospital, Chengdu, China; Department of Oncology, The Third People's Hospital of Sichuan Province, Chengdu, China
| | - Y Tang
- Sichuan Cancer Hospital, Chengdu, China
| | - M Fan
- Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - L Li
- Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - S Wang
- APHP, Hopitaux Universitaires Henri Mondor. Service d'Oncologie-Radiothérapie, Créteil, France
| | - Q Yin
- The Third People's Hospital of Sichuan Province, Chengdu, China
| | - H Ai
- Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
| | - S Zhao
- Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
| | - Y Yin
- Sichuan Institute of Brain Science and Brain-like Intelligence, Chengdu, China
| | - D Liu
- Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
| | - Y Ren
- Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
| | - J Li
- Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - F Li
- sichuan cancer hospital and institution, Chengdu, China
| | - J Lang
- Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
| |
Collapse
|
5
|
Feng M, Zhao S, Fan M, Li L, Wang S, Ai H, Tang Y, Yin Y, Ren Y, Li J, Li F, Lang J. Long-Term Survival Outcome for Metastatic Nasopharyngeal Carcinoma Patients Receiving Radiation to Primary and Metastatic Sites with Palliative Chemotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e581. [PMID: 37785765 DOI: 10.1016/j.ijrobp.2023.06.1922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) A total of 6% - 8% of NPC patients were initial diagnosed as distant metastatic disease. The median overall survival (OS) is only 10-15 months with palliative chemotherapy for these patients. A phase III study showed that palliative chemotherapy combined with radical radiotherapy to primary site could be a newly effective treatment method for metastatic NPC. Another phase 2, RCT found that the patients who had the solid tumors with 1-5 metastases received standard palliative care plus stereotactic body radiation therapy (SABR), and the 5-year OS were improved to 42.3%. Nevertheless, there was few studies focus on the radiation to both primary site and metastatic lesions. Therefore, we aimed to investigate the potential clinical benefits for initial diagnosed metastatic NPC patients with radiation to both primary site and distant metastatic lesions plus palliative chemotherapy. MATERIALS/METHODS Metastatic NPC patients treated with radiation to both primary site and distant metastatic lesions plus palliative chemotherapy were retrospectively collected in our hospital from May 2008 to May 2022. For treatment group, all patients underwent IGRT according to ICRU reports 50 and 62. The prescribed dose for primary site: GTVT: ≥66Gy, GTVn: ≥66Gy, CTV1: 60-66Gy, CTV2 54-60Gy, CTVln 50-54Gy. And the prescribed dose for distant metastatic lesions was more than 30Gy. For the control group, the patients treated with palliative chemotherapy were selected by propensity score matching from our hospital. The regimen for palliative chemotherapy was cisplatin-based chemotherapy every three weeks (100mg/m2 D1) for both groups. Kaplan-Meier method was used to analyze the OS. Cox regression model was used for multivariate analysis. RESULTS A total of 54 metastatic NPC patients with radiation to both primary site and distant metastatic lesions were retrospectively included in the treatment group, and another 54 patients were selected as the control group. The median follow-up time was 52 months. In the treatment group, the median age was 52 years (37-82), male (68%), female (32%), the main metastatic sites were bone (36 cases, 66%), lung (18 cases, 33%) and liver (10 cases, 18%). There were 23 oligometastasis cases and 31 cases. 3-year and 5-year OS in the treatment group were both dramatically improved than control group (63.2% vs 50.6%, p<0.05; 49.6% vs 38.9%, p<0.05). Multivariate analysis showed that T stage, liver metastatic lesion and oligometastases were the independent prognostic factors for them. CONCLUSION Palliative chemotherapy combined with radiation to primary sites and distant metastatic lesions might improve the OS for initial diagnosed distant metastatic NPC patients. More prospective clinical trials were needed to confirm it further.
Collapse
Affiliation(s)
- M Feng
- Sichuan Cancer Hospital, Chengdu, China; Department of Oncology, The Third People's Hospital of Sichuan Province, Chengdu, China
| | - S Zhao
- Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
| | - M Fan
- Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - L Li
- Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - S Wang
- University of Nebraska Medical Center, Omaha, NE
| | - H Ai
- Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
| | - Y Tang
- Sichuan Cancer Hospital, Chengdu, China
| | - Y Yin
- Sichuan Institute of Brain Science and Brain-like Intelligence, Chengdu, China
| | - Y Ren
- Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
| | - J Li
- Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - F Li
- Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - J Lang
- Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
| |
Collapse
|
6
|
Xu X, Wang H, Lu X, Fan M, Luo A, Liu M, Wang Y, Duan X. Sodium p-hydroxybenzoate alleviates osteoporosis through inhibiting bone metabolism and oxidative stress via activating ERα. Pak J Pharm Sci 2023; 36:1415-1424. [PMID: 37869917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 10/24/2023]
Abstract
As the population ages, the incidence of osteoporosis (OP) gradually increases and is becoming a growing public health problem. Meanwhile, although traditional pharmacological therapy is extremely efficient in the treatment of OP, its application is constrained because of irreversible adverse drug reactions. Therefore, scientists should actively develop safer drugs while ensuring the therapeutic effect of OP. Previous studies have shown that p-hydroxybenzoic acid (HA) can upregulate the expression of estrogen receptor (ER). Sodium p-hydroxybenzoate (DSN160) is a sodium salt of HA with a lethal dose greater than 5g/kg. However, whether DSN160 has demonstrable anti-osteoporotic activities remains unclear. In this study, DSN160 increased the organ index, length and diameter of the bone and bone mineral density and improved bone microstructure in retinoic acid-induced OP rats. Furthermore, DSN160 reduced bone metabolism-related indicators. In addition, fulvestrant (a specific antagonist of ER) blocked the anti-OP effect of DSN160. In conclusion, our findings showed that DSN160 exerts anti-OP effect through inhibiting bone metabolism and oxidative stress via activating ERα.
Collapse
Affiliation(s)
- Xiaotian Xu
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Huideng Wang
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Xi Lu
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Miaozhen Fan
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Ailin Luo
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Meng Liu
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Yuhui Wang
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Xiaoqun Duan
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| |
Collapse
|
7
|
Wang XH, Wang SY, Peng HX, Fan M, Guo HD, Hou TJ, Wang MY, Wu YQ, Qin XY, Tang X, Li J, Chen DF, Hu YH, Wu T. [Genotype-environment interaction on arterial stiffness: A pedigree-based study]. Beijing Da Xue Xue Bao Yi Xue Ban 2023; 55:400-407. [PMID: 37291913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
OBJECTIVE To utilized the baseline data of the Beijing Fangshan Family Cohort Study, and to estimate whether the association between a healthy lifestyle and arterial stiffness might be modified by genetic effects. METHODS Probands and their relatives from 9 rural areas in Fangshan district, Beijing were included in this study. We developed a healthy lifestyle score based on five lifestyle behaviors: smoking, alcohol consumption, body mass index (BMI), dietary pattern, and physical activity. The measurements of arterial stiffness were brachial-ankle pulse wave velocity (baPWV) and ankle-brachial index (ABI). A variance component model was used to determine the heritability of arterial stiffness. Genotype-environment interaction effects were performed by the maximum likelihood methods. Subsequently, 45 candidate single nucleotide polymorphisms (SNPs) located in the glycolipid metabolism pathway were selected, and generalized estimated equations were used to assess the gene-environment interaction effects between particular genetic loci and healthy lifestyles. RESULTS A total of 6 302 study subjects across 3 225 pedigrees were enrolled in this study, with a mean age of 56.9 years and 45.1% male. Heritability of baPWV and ABI was 0.360 (95%CI: 0.302-0.418) and 0.243 (95%CI: 0.175-0.311), respectively. Significant genotype-healthy diet interaction on baPWV and genotype-BMI interaction on ABI were observed. Following the findings of genotype-environment interaction analysis, we further identified two SNPs located in ADAMTS9-AS2 and CDH13 might modify the association between healthy dietary pattern and arterial stiffness, indicating that adherence to a healthy dietary pattern might attenuate the genetic risk on arterial stiffness. Three SNPs in CDKAL1, ATP8B2 and SLC30A8 were shown to interact with BMI, implying that maintaining BMI within a healthy range might decrease the genetic risk of arterial stiffness. CONCLUSION The current study discovered that genotype-healthy dietary pattern and genotype-BMI interactions might affect the risk of arterial stiffness. Furthermore, we identified five genetic loci that might modify the relationship between healthy dietary pattern and BMI with arterial stiffness. Our findings suggested that a healthy lifestyle may reduce the genetic risk of arterial stiffness. This study has laid the groundwork for future research exploring mechanisms of arterial stiffness.
Collapse
Affiliation(s)
- X H Wang
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - S Y Wang
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - H X Peng
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - M Fan
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - H D Guo
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - T J Hou
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - M Y Wang
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - Y Q Wu
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - X Y Qin
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - X Tang
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - J Li
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - D F Chen
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - Y H Hu
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
| | - T Wu
- Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
- Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Beijing 100191, China
| |
Collapse
|
8
|
Peng HX, Wang SY, Wang MY, Wang XH, Fan M, Guo HD, Hou TJ, Hao YT, Ren T, Wu T. [The role of the high-level public health school in the development of the Center for Disease Control and Prevention]. Zhonghua Liu Xing Bing Xue Za Zhi 2023; 44:662-666. [PMID: 37147842 DOI: 10.3760/cma.j.cn112338-20221103-00939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
The Ministry of Education and other four departments jointly issued the Notice on the Construction of high-level schools of public Health, proposing that "it will take ten years to build a number of high-level schools of public health, and form a high-quality education development system to adapt to the construction of modern public health system". At present, the construction of high-level public health schools in various universities in China is in full swing. The high-level School of Public Health and the CDC have played an important role in constructing the national public health system and the human health community. The high-level public health schools are of strategic significance and important value to the development of the CDC. The review presents reflections and insights on the role of high-level public health schools in the development of the CDC and the challenges they might face.
Collapse
Affiliation(s)
- H X Peng
- School of Public Health, Peking University, Beijing 100191, China
| | - S Y Wang
- School of Public Health, Peking University, Beijing 100191, China
| | - M Y Wang
- School of Public Health, Peking University, Beijing 100191, China
| | - X H Wang
- School of Public Health, Peking University, Beijing 100191, China
| | - M Fan
- School of Public Health, Peking University, Beijing 100191, China
| | - H D Guo
- School of Public Health, Peking University, Beijing 100191, China
| | - T J Hou
- School of Public Health, Peking University, Beijing 100191, China
| | - Y T Hao
- Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China
| | - T Ren
- School of Public Health, Peking University, Beijing 100191, China
| | - T Wu
- School of Public Health, Peking University, Beijing 100191, China
| |
Collapse
|
9
|
Chen J, Zhang H, Wang B, Wen J, Xu X, Li H, Fan M. 18P Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): An update of the phase II, prospective study. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00272-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
10
|
Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard JL, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C, Hamdi-Chérif M, Kara L, Meguenni K, Regagba D, Bayo S, Cheick Bougadari T, Manraj SS, Bendahhou K, Ladipo A, Ogunbiyi OJ, Somdyala NIM, Chaplin MA, Moreno F, Calabrano GH, Espinola SB, Carballo Quintero B, Fita R, Laspada WD, Ibañez SG, Lima CA, Da Costa AM, De Souza PCF, Chaves J, Laporte CA, Curado MP, de Oliveira JC, Veneziano CLA, Veneziano DB, Almeida ABM, Latorre MRDO, Rebelo MS, Santos MO, Azevedo e Silva G, Galaz JC, Aparicio Aravena M, Sanhueza Monsalve J, Herrmann DA, Vargas S, Herrera VM, Uribe CJ, Bravo LE, Garcia LS, Arias-Ortiz NE, Morantes D, Jurado DM, Yépez Chamorro MC, Delgado S, Ramirez M, Galán Alvarez YH, Torres P, Martínez-Reyes F, Jaramillo L, Quinto R, Castillo J, Mendoza M, Cueva P, Yépez JG, Bhakkan B, Deloumeaux J, Joachim C, Macni J, Carrillo R, Shalkow Klincovstein J, Rivera Gomez R, Perez P, Poquioma E, Tortolero-Luna G, Zavala D, Alonso R, Barrios E, Eckstrand A, Nikiforuk C, Woods RR, Noonan G, Turner D, Kumar E, Zhang B, Dowden JJ, Doyle GP, Saint-Jacques N, Walsh G, Anam A, De P, McClure CA, Vriends KA, Bertrand C, Ramanakumar AV, Davis L, Kozie S, Freeman T, George JT, Avila RM, O’Brien DK, Holt A, Almon L, Kwong S, Morris C, Rycroft R, Mueller L, Phillips CE, Brown H, Cromartie B, Ruterbusch J, Schwartz AG, Levin GM, Wohler B, Bayakly R, Ward KC, Gomez SL, McKinley M, Cress R, Davis J, Hernandez B, Johnson CJ, Morawski BM, Ruppert LP, Bentler S, Charlton ME, Huang B, Tucker TC, Deapen D, Liu L, Hsieh MC, Wu XC, Schwenn M, Stern K, Gershman ST, Knowlton RC, Alverson G, Weaver T, Desai J, Rogers DB, Jackson-Thompson J, Lemons D, Zimmerman HJ, Hood M, Roberts-Johnson J, Hammond W, Rees JR, Pawlish KS, Stroup A, Key C, Wiggins C, Kahn AR, Schymura MJ, Radhakrishnan S, Rao C, Giljahn LK, Slocumb RM, Dabbs C, Espinoza RE, Aird KG, Beran T, Rubertone JJ, Slack SJ, Oh J, Janes TA, Schwartz SM, Chiodini SC, Hurley DM, Whiteside MA, Rai S, Williams MA, Herget K, Sweeney C, Kachajian J, Keitheri Cheteri MB, Migliore Santiago P, Blankenship SE, Conaway JL, Borchers R, Malicki R, Espinoza J, Grandpre J, Weir HK, Wilson R, Edwards BK, Mariotto A, Rodriguez-Galindo C, Wang N, Yang L, Chen JS, Zhou Y, He YT, Song GH, Gu XP, Mei D, Mu HJ, Ge HM, Wu TH, Li YY, Zhao DL, Jin F, Zhang JH, Zhu FD, Junhua Q, Yang YL, Jiang CX, Biao W, Wang J, Li QL, Yi H, Zhou X, Dong J, Li W, Fu FX, Liu SZ, Chen JG, Zhu J, Li YH, Lu YQ, Fan M, Huang SQ, Guo GP, Zhaolai H, Wei K, Chen WQ, Wei W, Zeng H, Demetriou AV, Mang WK, Ngan KC, Kataki AC, Krishnatreya M, Jayalekshmi PA, Sebastian P, George PS, Mathew A, Nandakumar A, Malekzadeh R, Roshandel G, Keinan-Boker L, Silverman BG, Ito H, Koyanagi Y, Sato M, Tobori F, Nakata I, Teramoto N, Hattori M, Kaizaki Y, Moki F, Sugiyama H, Utada M, Nishimura M, Yoshida K, Kurosawa K, Nemoto Y, Narimatsu H, Sakaguchi M, Kanemura S, Naito M, Narisawa R, Miyashiro I, Nakata K, Mori D, Yoshitake M, Oki I, Fukushima N, Shibata A, Iwasa K, Ono C, Matsuda T, Nimri O, Jung KW, Won YJ, Alawadhi E, Elbasmi A, Ab Manan A, Adam F, Nansalmaa E, Tudev U, Ochir C, Al Khater AM, El Mistiri MM, Lim GH, Teo YY, Chiang CJ, Lee WC, Buasom R, Sangrajrang S, Suwanrungruang K, Vatanasapt P, Daoprasert K, Pongnikorn D, Leklob A, Sangkitipaiboon S, Geater SL, Sriplung H, Ceylan O, Kög I, Dirican O, Köse T, Gurbuz T, Karaşahin FE, Turhan D, Aktaş U, Halat Y, Eser S, Yakut CI, Altinisik M, Cavusoglu Y, Türkköylü A, Üçüncü N, Hackl M, Zborovskaya AA, Aleinikova OV, Henau K, Van Eycken L, Atanasov TY, Valerianova Z, Šekerija M, Dušek L, Zvolský M, Steinrud Mørch L, Storm H, Wessel Skovlund C, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier AM, Guizard AV, Bouvier V, Launoy G, Dabakuyo Yonli S, Poillot ML, Maynadié M, Mounier M, Vaconnet L, Woronoff AS, Daoulas M, Robaszkiewicz M, Clavel J, Poulalhon C, Desandes E, Lacour B, Baldi I, Amadeo B, Coureau G, Monnereau A, Orazio S, Audoin M, D’Almeida TC, Boyer S, Hammas K, Trétarre B, Colonna M, Delafosse P, Plouvier S, Cowppli-Bony A, Molinié F, Bara S, Ganry O, Lapôtre-Ledoux B, Daubisse-Marliac L, Bossard N, Uhry Z, Estève J, Stabenow R, Wilsdorf-Köhler H, Eberle A, Luttmann S, Löhden I, Nennecke AL, Kieschke J, Sirri E, Justenhoven C, Reinwald F, Holleczek B, Eisemann N, Katalinic A, Asquez RA, Kumar V, Petridou E, Ólafsdóttir EJ, Tryggvadóttir L, Murray DE, Walsh PM, Sundseth H, Harney M, Mazzoleni G, Vittadello F, Coviello E, Cuccaro F, Galasso R, Sampietro G, Giacomin A, Magoni M, Ardizzone A, D’Argenzio A, Di Prima AA, Ippolito A, Lavecchia AM, Sutera Sardo A, Gola G, Ballotari P, Giacomazzi E, Ferretti S, Dal Maso L, Serraino D, Celesia MV, Filiberti RA, Pannozzo F, Melcarne A, Quarta F, Andreano A, Russo AG, Carrozzi G, Cirilli C, Cavalieri d’Oro L, Rognoni M, Fusco M, Vitale MF, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Boschetti L, Marguati S, Chiaranda G, Seghini P, Maule MM, Merletti F, Spata E, Tumino R, Mancuso P, Cassetti T, Sassatelli R, Falcini F, Giorgetti S, Caiazzo AL, Cavallo R, Piras D, Bella F, Madeddu A, Fanetti AC, Maspero S, Carone S, Mincuzzi A, Candela G, Scuderi T, Gentilini MA, Rizzello R, Rosso S, Caldarella A, Intrieri T, Bianconi F, Contiero P, Tagliabue G, Rugge M, Zorzi M, Beggiato S, Brustolin A, Gatta G, De Angelis R, Vicentini M, Zanetti R, Stracci F, Maurina A, Oniščuka M, Mousavi M, Steponaviciene L, Vincerževskienė I, Azzopardi MJ, Calleja N, Siesling S, Visser O, Johannesen TB, Larønningen S, Trojanowski M, Macek P, Mierzwa T, Rachtan J, Rosińska A, Kępska K, Kościańska B, Barna K, Sulkowska U, Gebauer T, Łapińska JB, Wójcik-Tomaszewska J, Motnyk M, Patro A, Gos A, Sikorska K, Bielska-Lasota M, Didkowska JA, Wojciechowska U, Forjaz de Lacerda G, Rego RA, Carrito B, Pais A, Bento MJ, Rodrigues J, Lourenço A, Mayer-da-Silva A, Coza D, Todescu AI, Valkov MY, Gusenkova L, Lazarevich O, Prudnikova O, Vjushkov DM, Egorova A, Orlov A, Pikalova LV, Zhuikova LD, Adamcik J, Safaei Diba C, Zadnik V, Žagar T, De-La-Cruz M, Lopez-de-Munain A, Aleman A, Rojas D, Chillarón RJ, Navarro AIM, Marcos-Gragera R, Puigdemont M, Rodríguez-Barranco M, Sánchez Perez MJ, Franch Sureda P, Ramos Montserrat M, Chirlaque López MD, Sánchez Gil A, Ardanaz E, Guevara M, Cañete-Nieto A, Peris-Bonet R, Carulla M, Galceran J, Almela F, Sabater C, Khan S, Pettersson D, Dickman P, Staehelin K, Struchen B, Egger Hayoz C, Rapiti E, Schaffar R, Went P, Mousavi SM, Bulliard JL, Maspoli-Conconi M, Kuehni CE, Redmond SM, Bordoni A, Ortelli L, Chiolero A, Konzelmann I, Rohrmann S, Wanner M, Broggio J, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Morrison DS, Thomson CS, Greene G, Huws DW, Grayson M, Rawcliffe H, Allemani C, Coleman MP, Di Carlo V, Girardi F, Matz M, Minicozzi P, Sanz N, Ssenyonga N, James D, Stephens R, Chalker E, Smith M, Gugusheff J, You H, Qin Li S, Dugdale S, Moore J, Philpot S, Pfeiffer R, Thomas H, Silva Ragaini B, Venn AJ, Evans SM, Te Marvelde L, Savietto V, Trevithick R, Aitken J, Currow D, Fowler C, Lewis C. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol 2023; 25:580-592. [PMID: 36355361 PMCID: PMC10013649 DOI: 10.1093/neuonc/noac217] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. METHODS We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. RESULTS The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. CONCLUSIONS To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.
Collapse
Affiliation(s)
- Fabio Girardi
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.,Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Melissa Matz
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | - Charles Stiller
- National Cancer Registration and Analysis Service, Public Health England, London, UK
| | - Hui You
- Cancer Information Analysis Unit, Cancer Institute NSW, St Leonards, New South Wales, Australia
| | - Rafael Marcos Gragera
- Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain
| | - Mikhail Y Valkov
- Department of Radiology, Radiotherapy and Oncology, Northern State Medical University, Arkhangelsk, Russia
| | - Jean-Luc Bulliard
- Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.,Neuchâtel and Jura Tumour Registry, Neuchâtel, Switzerland
| | - Prithwish De
- Surveillance and Cancer Registry, and Research Office, Clinical Institutes and Quality Programs, Ontario Health, Toronto, Ontario, Canada
| | - David Morrison
- Scottish Cancer Registry, Public Health Scotland, Edinburgh, UK
| | - Miriam Wanner
- Cancer Registry Zürich, Zug, Schaffhausen and Schwyz, University Hospital Zürich, Zürich, Switzerland
| | - David K O'Brian
- Alaska Cancer Registry, Alaska Department of Health and Social Services, Anchorage, Alaska, USA
| | - Nathalie Saint-Jacques
- Department of Medicine and Community Health and Epidemiology, Centre for Clinical Research, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Michel P Coleman
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK
| | - Claudia Allemani
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Wang SY, Peng HX, Xue EC, Chen X, Wang XH, Fan M, Wang MY, Li N, Li J, Zhou ZB, Zhu HP, Hu YH, Wu T. [Progress in research of risk prediction of non-syndromic oral clefts using genetic information]. Zhonghua Liu Xing Bing Xue Za Zhi 2023; 44:504-510. [PMID: 36942349 DOI: 10.3760/cma.j.cn112338-20220624-00556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/23/2023]
Abstract
Non-syndromic oral cleft (NSOC), a common birth defect, remains to be a critical public health problem in China. In the context of adjustment of childbearing policy for two times in China and the increase of pregnancy at older childbearing age, NSOC risk prediction will provide evidence for high-risk population identification and prenatal counseling. Genome-wide association study and second generation sequencing have identified multiple loci associated with NSOC, facilitating the development of genetic risk prediction of NSOC. Despite the marked progress, risk prediction models of NSOC still faces multiple challenges. This paper summarizes the recent progress in research of NSOC risk prediction models based on the results of extensive literature retrieval to provide some insights for the model development regarding research design, variable selection, model-build strategy and evaluation methods.
Collapse
Affiliation(s)
- S Y Wang
- Department of Epidemiology and Biostatistics,School of Public Health,Peking University, Beijing 100191, China
| | - H X Peng
- Department of Epidemiology and Biostatistics,School of Public Health,Peking University, Beijing 100191, China
| | - E C Xue
- Department of Epidemiology and Biostatistics,School of Public Health,Peking University, Beijing 100191, China
| | - X Chen
- Department of Epidemiology and Biostatistics,School of Public Health,Peking University, Beijing 100191, China
| | - X H Wang
- Department of Epidemiology and Biostatistics,School of Public Health,Peking University, Beijing 100191, China
| | - M Fan
- Department of Epidemiology and Biostatistics,School of Public Health,Peking University, Beijing 100191, China
| | - M Y Wang
- Department of Epidemiology and Biostatistics,School of Public Health,Peking University, Beijing 100191, China
| | - N Li
- Department of Oral and Maxillofacial Surgery, School of Stomatology, Peking University, Beijing 100081, China
| | - J Li
- Department of Pediatrics, School of Stomatology, Peking University, Beijing 100081, China
| | - Z B Zhou
- Department of Oral and Maxillofacial Surgery, School of Stomatology, Peking University, Beijing 100081, China
| | - H P Zhu
- Department of Oral and Maxillofacial Surgery, School of Stomatology, Peking University, Beijing 100081, China
| | - Y H Hu
- Department of Epidemiology and Biostatistics,School of Public Health,Peking University, Beijing 100191, China
| | - T Wu
- Department of Epidemiology and Biostatistics,School of Public Health,Peking University, Beijing 100191, China Institute of Reproductive and Child Health/Key Laboratory of Reproductive Health, National Health Commission of the People's Republic of China, Beijing 100191, China
| |
Collapse
|
12
|
Huang J, Song Y, Kou X, Tan Z, Zhang S, Sun M, Zhou J, Fan M, Zhang M, Song Y, Li S, Yuan Y, Zhuang W, Zhang J, Zhang L, Jiang H, Gu K, Ye H, Wang Q, Zhu J. 69O First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
13
|
Feng M, Du X, Yin Y, Yan L, Wang H, Yin Q, Li L, Fan M, Lai X, Huang Y, Ren J, Lang J. Early Prediction Model of Radiation-Induced Xerostomia Based on Radiomics during Radiotherapy for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
14
|
Chen J, Zhang H, Wang B, Wen J, Xu X, Li H, Fan M. 375P Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): A phase II, prospective study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
15
|
Chen X, Wang SY, Xue EC, Wang XH, Peng HX, Fan M, Wang MY, Wu YQ, Qin XY, Li J, Wu T, Zhu J, Li ZP, Zhou DF, Chen YH, Hu Y. [Family-based association tests for rare variants]. Zhonghua Liu Xing Bing Xue Za Zhi 2022; 43:1497-1502. [PMID: 36117360 DOI: 10.3760/cma.j.cn112338-20211224-01013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Next-generation sequencing has revolutionized family-based association tests for rare variants. As the lower power of genome wide association study for detecting casual rare variants, methods aggregating effects of multiple variants have been proposed, such as burden tests and variance component tests. This paper summarizes the methods of rare variants association test that can be applied for family data, introduces their principles, characteristics and applicable conditions and discusses the shortcomings and the improvement of the present methods.
Collapse
Affiliation(s)
- X Chen
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - S Y Wang
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - E C Xue
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - X H Wang
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - H X Peng
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - M Fan
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - M Y Wang
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - Y Q Wu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - X Y Qin
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - J Li
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - T Wu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - J Zhu
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, China
| | - Z P Li
- Department of Pediatric Dentistry, Peking University School and Hospital of Stomatology, Beijing 100081, China
| | - D F Zhou
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, China
| | - Y H Chen
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - Yonghua Hu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| |
Collapse
|
16
|
Wang Y, Fan M, Wang H, You Y, Wei C, Liu M, Luo A, Xu X, Duan X. Relative safety and efficacy of topical and oral NSAIDs in the treatment of osteoarthritis: A systematic review and meta-analysis. Medicine (Baltimore) 2022; 101:e30354. [PMID: 36086745 PMCID: PMC10980447 DOI: 10.1097/md.0000000000030354] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 07/20/2022] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Osteoarthritis (OA) often affects the hands, knees, and hip joints, causing considerable pain and disability, and often affecting the patient's quality of life. Non-steroidal anti-inflammatory drugs (NSAIDs) are common pain relievers often applied as first line therapies for OA. However, prolonged NSAIDs application can have unwanted side effects. Given this, this study was designed to systematically evaluate the efficacy and safety of topical and oral NSAIDs for the treatment of OA. METHODS We searched the PubMed, Embase, Cochrane Library, and Web of Science databases for relevant papers from their inception dates to May 2021. Our study only included randomized controlled trials comparing topical and oral NSAIDs and all data were analyzed using Review Manager version 5.3 (RevMan version 5.3). RESULTS We identified 8 RCTs (2096 patients with OA), for evaluation and revealed that, in general, topical and oral NSAIDs presented with similar efficacies for the treatment of OA. The Western Ontario and McMaster Osteoarthritis Index for assessing pain relief in OA patients was (standardized mean difference [SMD] 0.07; 95%CI -0.02, 0.17) and visual analog scale was (SMD -0.01; 95%CI -0.02, 0.18), and improved stiffness in OA patients (SMD 0.09; 95%Cl 0.03, 0.20). CONCLUSIONS Topical NSAIDs are as effective as oral NSAIDs for the treatment of OA and both topical and oral NSAIDs are equally effective in reducing pain and improving physical function in OA patients. In terms of safety, a larger number of samples are still needed to determine if there are any differences in the safety profile of topical or oral NSAIDs. REGISTRATION NUMBER INPLASY 2021110009.
Collapse
Affiliation(s)
- Yuhui Wang
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Miaozhen Fan
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Huideng Wang
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Yi You
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Chengqiong Wei
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Meng Liu
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Ailin Luo
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Xiaotian Xu
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| | - Xiaoqun Duan
- Guangxi Colleges and Universities Key Laboratory of pharmacology, Guilin Medical University, Guilin, Guangxi, China
| |
Collapse
|
17
|
Li X, Yin D, Fan M, Yang Y, Liang L, Feng N, Li X, Guo F. [IRE1 α deficiency impairs autophagy in chondrocytes by upregulating calcium homeostasis endoplasmic reticulum protein]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42:785-793. [PMID: 35790428 DOI: 10.12122/j.issn.1673-4254.2022.06.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To explore the mechanism by which inositol-requiring enzyme-1α (IRE1α) regulates autophagy function of chondrocytes through calcium homeostasis endoplasmic reticulum protein (CHERP). METHODS Cultured human chondrocytes (C28/I2 cells) were treated with tunicamycin, 4μ8c, rapamycin, or both 4μ8c and rapamycin, and the expressions of endoplasmic reticulum (ER) stress- and autophagy-related proteins were detected with Western blotting. Primary chondrocytes from ERN1 knockout (ERN1 CKO) mice and wild-type mice were examined for ATG5 and ATG7 mRNA expressions, IRE1α and p-IRE1α protein expressions, and intracellular calcium ion content using qPCR, Western blotting and flow cytometry. The effect of bafilomycin A1 treatment on LC3 Ⅱ/LC3 Ⅰ ratio in the isolated chondrocytes was assessed with Western blotting. Changes in autophagic flux of the chondrocytes in response to rapamycin treatment were detected using autophagy dual fluorescent virus. The changes in autophagy level in C28/I2 cells overexpressing CHERP and IRE1α were detected using immunofluorescence assay. RESULTS Tunicamycin treatment significantly up-regulated ER stress-related proteins and LC3 Ⅱ/LC3 Ⅰ ratio and down-regulated the expression of p62 in C28/I2 cells (P < 0.05). Rapamycin obviously up-regulated LC3 Ⅱ/LC3 Ⅰ ratio (P < 0.001) in C28/I2 cells, but this effect was significantly attenuated by co-treatment with 4μ8c (P < 0.05). Compared with the cells from the wild-type mice, the primary chondrocytes from ERN1 knockout mice showed significantly down-regulated mRNA levels of ERN1 (P < 0.01), ATG5 (P < 0.001) and ATG7 (P < 0.001), lowered or even lost expressions of IRE1α and p-IRE1α proteins (PP < 0.01), and increased expression of CHERP (P < 0.05) and intracellular calcium ion content (P < 0.001). Bafilomycin A1 treatment obviously increased LC3 Ⅱ/ LC3 Ⅰ ratio in the chondrocytes from both wild-type and ERN1 knockout mice (P < 0.01 or 0.05), but the increment was more obvious in the wild-type chondrocytes (P < 0.05). Treatment with autophagy dual-fluorescence virus resulted in a significantly greater fluorescence intensity of LC3-GFP in rapamycin-treated ERN1 CKO chondrocytes than in wild-type chondrocytes (P < 0.05). In C28/I2 cells, overexpression of CHERP obviously decreased the fluorescence intensity of LC3, and overexpression of IRE1α enhanced the fluorescence intensity and partially rescued the fluorescence reduction of LC3 caused by CHERP. CONCLUSION IRE1α deficiency impairs autophagy in chondrocytes by upregulating CHERP and increasing intracellular calcium ion content.
Collapse
Affiliation(s)
- X Li
- Department of Cell Biology and Genetics, Chongqing Medical University, Chongqing 400016, China
| | - D Yin
- Department of Pathology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing 100011, China
| | - M Fan
- Department of Cell Biology and Genetics, Chongqing Medical University, Chongqing 400016, China
| | - Y Yang
- Department of Cell Biology and Genetics, Chongqing Medical University, Chongqing 400016, China
| | - L Liang
- Department of Cell Biology and Genetics, Chongqing Medical University, Chongqing 400016, China
| | - N Feng
- Department of Cell Biology and Genetics, Chongqing Medical University, Chongqing 400016, China
| | - X Li
- Department of Cell Biology and Genetics, Chongqing Medical University, Chongqing 400016, China
| | - F Guo
- Department of Cell Biology and Genetics, Chongqing Medical University, Chongqing 400016, China
| |
Collapse
|
18
|
Ren T, Fan M, Xue EC, Yang J, Liu XY, Liu J, Chen H, Zhao CB, Chen X, Wang XH, Wu T, Guo ZJ, Wang YH, Hu Y. [Summary of tools for assessment of public health emergency response capability]. Zhonghua Liu Xing Bing Xue Za Zhi 2022; 43:397-402. [PMID: 35345297 DOI: 10.3760/cma.j.cn112338-20220112-00029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
With the progress of globalization, the public health emergencies represented by major infectious diseases have become a major challenge for the public health management in China. The article briefly describes the emergency response capability assessment tools in China, and introduces two emergency response assessment tools with complete content structure and wide application in the world. Then the advantages and disadvantages of the tools are compared and discussed in order to provide reference for improvement of the assessment tools for public health emergency response capability in China.
Collapse
Affiliation(s)
- T Ren
- School of Public Health, Peking University, Beijing 100191, China
| | - M Fan
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - E C Xue
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - J Yang
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing 100191, China
| | - X Y Liu
- China Centre for Health Development Studies, Peking University, Beijing 100191, China
| | - J Liu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - H Chen
- Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - C B Zhao
- School of Public Health, Peking University, Beijing 100191, China
| | - X Chen
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - X H Wang
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - T Wu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| | - Z J Guo
- Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Y H Wang
- Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China
| | - Yonghua Hu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
| |
Collapse
|
19
|
Holliman CA, Fan M, Contractor A, Brewer SM, Jayich AM. Radium Ion Optical Clock. Phys Rev Lett 2022; 128:033202. [PMID: 35119894 DOI: 10.1103/physrevlett.128.033202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Accepted: 12/15/2021] [Indexed: 06/14/2023]
Abstract
We report the first operation of a Ra^{+} optical clock, a promising high-performance clock candidate. The clock uses a single trapped ^{226}Ra^{+} ion and operates on the 7s ^{2}S_{1/2}→6d ^{2}D_{5/2} electric quadrupole transition. By self-referencing three pairs of symmetric Zeeman transitions, we demonstrate a frequency instability of 1.1×10^{-13}/sqrt[τ], where τ is the averaging time in seconds. The total systematic uncertainty is evaluated to be Δν/ν=9×10^{-16}. Using the clock, we realize the first measurement of the ratio of the D_{5/2} state to the S_{1/2} state Landé g-factors: g_{D}/g_{S}=0.598 805 3(11). A Ra^{+} optical clock could improve limits on the time variation of the fine structure constant, α[over ˙]/α, in an optical frequency comparison. The ion also has several features that make it a suitable system for a transportable optical clock.
Collapse
Affiliation(s)
- C A Holliman
- Department of Physics, University of California, Santa Barbara, California 93106, USA
| | - M Fan
- Department of Physics, University of California, Santa Barbara, California 93106, USA
| | - A Contractor
- Department of Physics, University of California, Santa Barbara, California 93106, USA
| | - S M Brewer
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - A M Jayich
- Department of Physics, University of California, Santa Barbara, California 93106, USA
| |
Collapse
|
20
|
Feng M, Yin Q, Qi Y, Li L, Lan M, Lai X, Fan M, Zhang J, Li F, Wang W, Lang J. PO-0978 Low-dose radiotherapy as a chemosensitizer of neoadjuvant chemotherapy for LA-NPC: a phase II trial. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07429-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Liu C, Wang J, Huang S, Chang J, Yu H, Zhu Z, Fan M. P47.01 Plasma Exosomal Long RNA in SCLC Diagnosis and Prognosis. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Chen YP, Zhang J, Chen B, Wang W, Fan M, Tao XY. [Clinical characteristics and outcome of pregnant patients with myasthenia gravis]. Zhonghua Nei Ke Za Zhi 2021; 60:117-121. [PMID: 33503721 DOI: 10.3760/cma.j.cn112138-20200415-00375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To study the clinical characteristics of pregnant patients with myasthenia gravis (MG) and the influence of MG to pregnancy. Methods: A retrospective study was conducted including 28 MG patients with 38 pregnancies admitted to the 8th Medical Center of PLA General Hospital between January 2013 and October 2018. Data were collected including clinical scores of MG, serum level of acetylcholine receptor (AChR) antibodies, abnormal repetitive nerve stimulation (RNS) and history of thymectomy before pregnancy. The course of pregnancy, delivery and neonatal outcome were also analyzed. According the outcome of MG, patients were divided into three groups, i.e. improvement group, stable group and deterioration group. Results: (1) The age of MG patients ranged from 21 to 36 (27±4) years. The previous course of MG was 0.5-17.2 (7.4±5.8)years. Based on Osserman clinical type, type ⅡA was the most common one [44.1% (15/34)], followed with type Ⅰ [29.4% (10/34)], type ⅡB [23.5% (8/34)] and type Ⅳ (2.9%).(2)There were 38 pregnancies in 28 women whose pregnancy outcomes resulted in one spontaneous abortion, three embryonic arrest and 34 live births. All abortions developed in the first trimester. Among the 34 pregnancies with live births, the symptoms of MG improved in 16 pregnancies (47.1%), whereas those deteriorated in 10 pregnancies (29.4%) during the first or third trimester and remained stable in 8 pregnancies (23.5%). (3) Compared with improvement group and stable group, the deterioration group had shorter duration of MG [(1.1±0.5) years vs. (7.1±5.1) years, (9.0±5.4) years respectively], higher clinical scores (20.9±6.0 vs. 14.8±6.6,13.3±5.0) and more frequent abnormal RNS(9/10 vs. 8/16, 4/8) and type ⅡB(6/10 vs. 1/16, 1/8) before pregnancy. Positive rate of serum AChR antibody and percentage of thymectomy before pregnancy were comparable between three groups. (4) Spinal anesthesia was performed in 23 pregnancies and 11 cases were vaginal delivery. No transient neonatal MG were found in live-born infants. Conclusions: Pregnancy in patients with under-controlled myasthenia gravis should not be discouraged. The outcome of MG is affected by the duration of MG, MG score and RNS before pregnancy. The first and third trimesters of pregnancy are considered high-risk periods for MG exacerbations. Neonatal transient myasthenia is uncommon, but the newborn should be carefully monitored by obstetricians and neurologists.
Collapse
Affiliation(s)
- Y P Chen
- Department of Neurology, the First Medical Center of PLA General Hospital, Beijing 100853,China
| | - J Zhang
- Department of Aspiration and Critical Care, the Eighth Medical Center of PLA General Hospital, Beijing 100091,China
| | - B Chen
- Department of Neurology, the First Medical Center of PLA General Hospital, Beijing 100853,China
| | - W Wang
- Department of Neurology, the First Medical Center of PLA General Hospital, Beijing 100853,China
| | - M Fan
- Department of Obstetrics and Gynecology, the Seventh Medical Center of PLA General Hospital, Beijing 100091,China
| | - X Y Tao
- Department of Neurology, the First Medical Center of PLA General Hospital, Beijing 100853,China
| |
Collapse
|
23
|
Fan M, Holliman CA, Shi X, Zhang H, Straus MW, Li X, Buechele SW, Jayich AM. Optical Mass Spectrometry of Cold RaOH^{+} and RaOCH_{3}^{+}. Phys Rev Lett 2021; 126:023002. [PMID: 33512224 DOI: 10.1103/physrevlett.126.023002] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Accepted: 11/04/2020] [Indexed: 06/12/2023]
Abstract
We present an all-optical mass spectrometry technique to identify trapped ions. The new method uses laser-cooled ions to determine the mass of a cotrapped dark ion with a sub-dalton resolution within a few seconds. We apply the method to identify the first controlled synthesis of cold, trapped RaOH^{+} and RaOCH_{3}^{+}. These molecules are promising for their sensitivity to time and parity violations that could constrain sources of new physics beyond the standard model. The nondestructive nature of the mass spectrometry technique may help identify molecular ions or highly charged ions prior to optical spectroscopy. Unlike previous mass spectrometry techniques for small ion crystals that rely on scanning, the method uses a Fourier transform that is inherently broadband and comparatively fast. The technique's speed provides new opportunities for studying state-resolved chemical reactions in ion traps.
Collapse
Affiliation(s)
- M Fan
- Department of Physics, University of California, Santa Barbara, California 93106, USA
- California Institute for Quantum Entanglement, Santa Barbara, California 93106, USA
| | - C A Holliman
- Department of Physics, University of California, Santa Barbara, California 93106, USA
- California Institute for Quantum Entanglement, Santa Barbara, California 93106, USA
| | - X Shi
- Department of Physics, University of California, Santa Barbara, California 93106, USA
- California Institute for Quantum Entanglement, Santa Barbara, California 93106, USA
| | - H Zhang
- CAS Key Laboratory of Quantum Information, University of Science and Technology of China, Hefei, 230026, China
| | - M W Straus
- Department of Physics, University of California, Santa Barbara, California 93106, USA
- California Institute for Quantum Entanglement, Santa Barbara, California 93106, USA
| | - X Li
- Key Laboratory for Physical Electronics and Devices of the Ministry of Education and Shaanxi Key Laboratory of Information Photonic Technique, Xi' an Jiaotong University, Xi' an 710049, China
| | - S W Buechele
- Department of Physics, University of California, Santa Barbara, California 93106, USA
- California Institute for Quantum Entanglement, Santa Barbara, California 93106, USA
| | - A M Jayich
- Department of Physics, University of California, Santa Barbara, California 93106, USA
- California Institute for Quantum Entanglement, Santa Barbara, California 93106, USA
| |
Collapse
|
24
|
Bao HL, Liu LY, Fang LW, Cong S, Fu ZT, Tang JL, Yang S, Shi WW, Fan M, Cao MQ, Guo XL, Sun JX, Geng CZ, Duan XN, Yu ZG, Wang LH. [The Breast Cancer Cohort Study in Chinese Women: the methodology of population-based cohort and baseline characteristics]. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:2040-2045. [PMID: 33378814 DOI: 10.3760/cma.j.cn112338-20200507-00695] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: Breast cancer has been the first cancer among women with the incidence increasing gradually. In September 2016, the Breast Cancer Cohort Study in Chinese Women (BCCS-CW) was initiated, aiming to establish a standardized and sharable breast cancer-specific cohort by integrating the existing cohort resource and improving the quality of follow-up. The BCCS-CW may provide a research basis and platform for the precision prevention and treatment of breast cancer in etiology identification, prevention, early diagnosis, treatment, and prognosis prediction. Methods: We conducted a population-based perspective cohort by questionnaire interview, anthropometry, biological specimens, breast ultrasound and mammography. The cohort was followed by using regional health surveillance and ad hoc survey. Results: Finally, BCCS-CW included 112 118 women, in which 55 419 women completed the standardized investigation and blood specimens were collected from 54 304 women. The mean age of participants was 51.7 years old, 62.7% were overweight or obese, and 48.9% were menopausal. Conclusion: The BCCS-CW will provide population-based cohort resource and research platform for the precise prevention and treatment of breast cancer in Chinese women.
Collapse
Affiliation(s)
- H L Bao
- National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - L Y Liu
- The Second Hospital of Shandong University, Ji'nan 250033, China
| | - L W Fang
- National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - S Cong
- National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - Z T Fu
- Shandong Center for Disease Control and Prevention, Ji'nan 250014, China
| | - J L Tang
- Shandong Center for Disease Control and Prevention, Ji'nan 250014, China
| | - S Yang
- The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang 050019, China
| | - W W Shi
- Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang 050021, China
| | - M Fan
- Taixing Center for Disease Control and Prevention, Taizhou 225400, China
| | - M Q Cao
- Taixing Center for Disease Control and Prevention, Taizhou 225400, China
| | - X L Guo
- Shandong Center for Disease Control and Prevention, Ji'nan 250014, China
| | - J X Sun
- Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang 050021, China
| | - C Z Geng
- The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang 050019, China
| | - X N Duan
- Breast Disease Center, Peking University First Hospital, Beijing 100034, China
| | - Z G Yu
- The Second Hospital of Shandong University, Ji'nan 250033, China
| | - L H Wang
- National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| |
Collapse
|
25
|
Wen J, Chen J, Jabbour S, Chen D, Zhang Z, Wang J, Fan M. Novel Approaches To Precisely Estimate Prognostic Significance Of Metastatic Lymph Nodes And Adequacy Of Lymphadenectomy On Esophageal Squamous Cell Carcinoma Patients: Beyond The Tip Of The Iceberg. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Ai D, Ye J, Chen Y, Liu Q, Zheng X, Yunhai L, Wei S, LI J, Lin Q, Luo H, Cao J, Zhou J, Huang G, Fan M, Wu K, Yang H, Zhu Z, Zhao W, Li L, Zhao K. Final Results of a Phase III Randomized Trial of Comparison of Three Paclitaxel-based Regimens Concurrent with Radiotherapy for Patients with Local Advanced Esophageal Squamous Cell Carcinoma (ESO-Shanghai2). Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Wen J, Chen J, Xu X, Liu D, Gu Y, Zhang J, Fan M. Abscopal Effects Induced by Radiotherapy Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Recurrent or Refractory Metastatic Thymic Epithelial Tumors: A Single-Institution Experience. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Kang J, Tchekmedyian V, Fan M, Wang H, Kitpanit S, Mohamed N, Rybkin A, Lee A, Chen L, Yu Y, Riaz N, McBride S, Tsai C, Ho A, Dunn L, Fetten J, Pfister D, Zhang Z, Lee N, Sherman E. Split High-Dose Cisplatin: An Alternate High-Dose Cisplatin Administration Schedule for Definitive Chemoradiation in Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
29
|
Yu Q, Fan M, Qiu H, Chan E, Goggins W, Hung I, Li X. PIN25 The IMPACT of Childhood Pneumococcal Conjugate Vaccine Immunisation on Pneumonia Admissions in Hong Kong: A Population-Based Interrupted Time Series Analysis from 2004-2017. Value Health Reg Issues 2020. [DOI: 10.1016/j.vhri.2020.07.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
30
|
Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z, Zhou J, Zhou C, Li B, Li J, Fan M, Zhang W, Yang W, Wang S, Zhou H. LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2289] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
31
|
Fan M, Chen X, Luo X, Zhang H, Liu Y, Zhang Y, Wu J, Zhao C, Zhao P. Diversity of endophytic fungi from the leaves of Vaccinium dunalianum. Lett Appl Microbiol 2020; 71:479-489. [PMID: 32619301 DOI: 10.1111/lam.13345] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 06/22/2020] [Accepted: 06/22/2020] [Indexed: 10/23/2022]
Abstract
This study was focus on investigating the community composition of endophytic fungi in the leaves of Vaccinium dunalianum Wight. Based on a combination of morphological features and molecular evidence, 239 endophytic fungal isolates belonging to 33 genera including 62 species were obtained and identified. By comparing the relative abundance (RA) values, the most frequent species belonged to Phyllosticta and Guignardia with RA of 26·78 and 14·22% respectively. Of which, the strains P. capitalensis and G. mangiferae with potential antimicrobial activity were the dominant endophytes to the sampling of leaves. A high diversity of endophytic fungi from V. dunalianum leaves was observed with high species richness S (62), Margalef index D' (11·1386), Shannon-Wiener index H' (3·2588), Simpson's diversity index Ds (0·9179), probability of interspecific encounter index (0·9218), and evenness Pielou index J (0·7896) but a low dominant index λ (0·0821). SIGNIFICANCE AND IMPACT OF THE STUDY: The isolated 239 endophytic fungal strains belong to 33 genera, 62 species, in which a high diversity of endophytic fungi was observed in Vaccinium dunalianum leaves. In this study, two taxa Phyllosticta capitalensis and Guignardia mangiferae with potential antimicrobial activity were the dominant endophytes. This is a promising source of natural bioactive compounds for future agro-industry application.
Collapse
Affiliation(s)
- M Fan
- Key Laboratory of State Forestry and Grassland Administration on Highly-Efficient Utilization of Forestry Biomass Resources in Southwest China, Southwest Forestry University, Kunming, People's Republic of China
| | - X Chen
- Key Laboratory of State Forestry and Grassland Administration on Highly-Efficient Utilization of Forestry Biomass Resources in Southwest China, Southwest Forestry University, Kunming, People's Republic of China
| | - X Luo
- Key Laboratory of State Forestry and Grassland Administration on Highly-Efficient Utilization of Forestry Biomass Resources in Southwest China, Southwest Forestry University, Kunming, People's Republic of China
| | - H Zhang
- Collaborative Innovation Center of Forest Resources Breeding and Utilization in Yunnan, Kunming, People's Republic of China
| | - Y Liu
- Collaborative Innovation Center of Forest Resources Breeding and Utilization in Yunnan, Kunming, People's Republic of China
| | - Y Zhang
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, People's Republic of China
| | - J Wu
- Key Laboratory of Forest Disaster Warning and Control of Yunnan Province, Southwest Forestry University, Kunming, People's Republic of China
| | - C Zhao
- Key Laboratory of Forest Disaster Warning and Control of Yunnan Province, Southwest Forestry University, Kunming, People's Republic of China
| | - P Zhao
- Key Laboratory of State Forestry and Grassland Administration on Highly-Efficient Utilization of Forestry Biomass Resources in Southwest China, Southwest Forestry University, Kunming, People's Republic of China.,Collaborative Innovation Center of Forest Resources Breeding and Utilization in Yunnan, Kunming, People's Republic of China
| |
Collapse
|
32
|
Fan D, Fan M, Wang H, Lee A, Yu Y, Chen L, Tsai C, McBride S, Riaz N, Bernstein M, Mueller B, Gelblum D, Fetten J, Dunn L, Michel L, Pfister D, Ho A, Boyle J, Cohen M, Roman B, Cracchiolo J, Morris L, Ganly I, Singh B, Shaha A, Patel S, Shah J, Wong R, Sherman E, Lee N, Kang J. Last-line Local Treatment with the Quad Shot Regimen for Previously Irradiated Head and Neck Cancers. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.135] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Kitpanit S, Lee A, Fan D, Fan M, Wang H, Mohamed N, Spielsinger D, Gelblum D, Sherman E, Dunn L, Boyle J, Wong R, Cohen M, Kang J, Tsai C, McBride S, Zakeri K, Chen L, Yu Y, Riaz N, Lee N. Clinical Outcomes and Toxicities in Oropharyngeal Cancer (OPC) Patients Treated with Proton Therapy: A Single Institutional Experience. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.231] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
34
|
Kang J, Cartano O, Fan D, Fan M, Wang H, Kitpanit S, Lee A, Gelblum D, Sherman E, Dunn L, Cohen M, Boyle J, Wong R, Tsai C, McBride S, Zakeri K, Chen L, Yu Y, Riaz N, Lee N. Changing the Paradigm in HPV-Negative Oropharyngeal Cancer: Deintensification Based on Low Risk of Locoregional Relapse. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
35
|
Fan M, Lee N, Lee A, Kang J, Fan D, Tsai C, Chen L. Improved Outcomes by proton beam radiation for nasal cavity and paranasal sinus malignances. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Li B, Hu H, Zhang Y, Zhang J, Miao L, Ma L, Luo X, Zhang Y, Ye T, Li H, Li Y, Shen L, Zhao K, Fan M, Zhu Z, Wang J, Xu J, Deng Y, Lu Q, Li H, Zhang Y, Pan Y, Liu S, Hu H, Shao L, Sun Y, Xiang J, Chen H. Three-field versus two-field lymphadenectomy in transthoracic oesophagectomy for oesophageal squamous cell carcinoma: short-term outcomes of a randomized clinical trial. Br J Surg 2020; 107:647-654. [PMID: 32108326 DOI: 10.1002/bjs.11497] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Revised: 10/10/2019] [Accepted: 12/10/2019] [Indexed: 11/10/2022]
Abstract
BACKGROUND The benefit and harm of three-field lymphadenectomy for oesophageal cancer are still unknown. The aim of this study was to compare overall survival and morbidity and mortality between three- and two-field lymphadenectomy in patients with oesophageal squamous cell carcinoma. METHODS Between March 2013 and November 2016, patients with squamous cell carcinoma of the middle or distal oesophagus were assigned randomly to open oesophagectomy with three-field (cervical-thoracic-abdominal) or two-field (thoracic-abdominal) lymphadenectomy. No chemo(radio) therapy was given before surgery. This paper reports on the secondary outcomes of the study: pathology and surgical complications. RESULTS Some 400 patients were randomized, 200 in each group. A median of 37 (i.q.r. 30-49) lymph nodes were dissected in the three-field group, compared with 24 (18-30) in the two-field group (P < 0·001). Some 43 of 200 patients (21·5 per cent) in the three-field group had cervical lymph node metastasis. More patients in the three-field group had pN3 disease: 21 of 200 (10·5 per cent) versus 10 of 200 (5·0 per cent) (P = 0·040). The rate and severity of postoperative complications were comparable between the two groups, except that six patients in the three-field arm needed reintubation compared with none in the two-field group (3·0 versus 0 per cent; P = 0·030). The 90-day mortality rate was 0 per cent in the three-field group and 0·5 per cent (1 patient) in the two-field group (P = 1·000). CONCLUSION Oesophagectomy with three-field lymphadenectomy increased the number of lymph nodes dissected and led to stage migration owing to a 21·5 per cent rate of cervical lymph node metastasis. Postoperative complications were largely comparable between two- and three-field lymphadenectomy. Registration number: NCT01807936 ( https://www.clinicaltrials.gov).
Collapse
Affiliation(s)
- B Li
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - H Hu
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Y Zhang
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - J Zhang
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - L Miao
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - L Ma
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - X Luo
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Y Zhang
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - T Ye
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - H Li
- Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Y Li
- Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - L Shen
- Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - K Zhao
- Department of Radiation Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - M Fan
- Department of Radiation Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Z Zhu
- Department of Radiation Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - J Wang
- Department of Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - J Xu
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China
| | - Y Deng
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Q Lu
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - H Li
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Y Zhang
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Y Pan
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - S Liu
- Department of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou, China
| | - H Hu
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - L Shao
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Y Sun
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - J Xiang
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - H Chen
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| |
Collapse
|
37
|
Chen T, Zhou Y, Luo L, Wu X, Li Z, Fan M, Zhao W. Preparation and characterization of heteroatom self-doped activated biocarbons as hydrogen storage and supercapacitor electrode materials. Electrochim Acta 2019. [DOI: 10.1016/j.electacta.2019.134941] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
Wen J, Chen J, Fan M, Xu X, Liu D. P1.17-18 Surgery Alone or Plus Adjuvant Radiotherapy for Patients with N0 Non-Small-Cell Lung Cancer >5 cm: A Population-Based Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Liu C, Wang J, Huang S, Chang J, Yu H, Zhu Z, Fan M. P1.12-19 Identification and Potential Application of Human Blood Exosomal RNA in Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
40
|
Xu X, Fan M, Chen J, Zhang J, Wen J, Liu D, Cao J, Gu Y. Abscopal Effect and Safety of Recurrent and Refractory Advanced Malignant Thymoma or Thymic Carcinoma Treated with Combined Therapy of Local Radiotherapy and Granulocyte-macrophage Colony-stimulating Factor. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Azgahdi S, Candas D, Xie B, Zhang L, Zhang Y, Fan M, Liu L, Sweeney C, Pan C, Ozpiskin O, Vaughan A, Wang J, Xia S, Monjazeb A, Woloschak G, Grdina D, Murphy W, Sun L, Chen H, Lam K, Weichselbaum R, Li J. Dual Blockade of CD47 and HER2 Re-sensitizes Resistant Breast Cancer Cells to Radiation Therapy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
42
|
Ai D, Chen Y, Liu Q, Zheng X, Yunhai L, Wei S, Ye J, Zhou J, Lin Q, Luo H, Cao J, LI J, Huang G, Wu K, Fan M, Yang H, Zhu Z, Zhao W, Li L, Zhao K. Safety Results of a Phase III Randomized Trial of Comparison of Three Paclitaxel-Based Regimens Concurrent with Radiotherapy for Patients with Local Advanced Esophageal Squamous Cell Carcinoma (ESO-Shanghai 2). Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
43
|
Abstract
The unstable radium nucleus is appealing for probing new physics due to its high mass, octupole deformation, and energy level structure. Ion traps, with long hold times and low particle numbers, are excellent for work with radioactive species, such as radium and radium-based molecular ions, where low activity, and hence low total numbers, is desirable. We address the challenges associated with the lack of stable isotopes in a tabletop experiment with a low-activity (∼10 μCi) source where we laser-cool trapped radium ions. With a laser-cooled radium ion we measured the 7p^{2}P_{1/2}^{o} state's branching fractions to the ground state, 7s^{2}S_{1/2}, and a metastable excited state, 6d^{2}D_{3/2}, to be p=0.9104(7) and 0.0896(7), respectively. With a nearby tellurium reference line we measured the 7s^{2}S_{1/2}→7p^{2}P_{1/2}^{o} transition frequency, 640.096 63(6) THz.
Collapse
Affiliation(s)
- M Fan
- Department of Physics, University of California, Santa Barbara, California 93106, USA and California Institute for Quantum Entanglement, Santa Barbara, California 93106, USA
| | - C A Holliman
- Department of Physics, University of California, Santa Barbara, California 93106, USA and California Institute for Quantum Entanglement, Santa Barbara, California 93106, USA
| | - A L Wang
- Department of Physics, University of California, Santa Barbara, California 93106, USA and California Institute for Quantum Entanglement, Santa Barbara, California 93106, USA
| | - A M Jayich
- Department of Physics, University of California, Santa Barbara, California 93106, USA and California Institute for Quantum Entanglement, Santa Barbara, California 93106, USA
| |
Collapse
|
44
|
Cao X, Ye Q, Fan M, Liu C. Antimicrobial effects of the ginsenoside Rh2 on monospecies and multispecies cariogenic biofilms. J Appl Microbiol 2019; 126:740-751. [PMID: 30556937 DOI: 10.1111/jam.14178] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Revised: 11/01/2018] [Accepted: 12/12/2018] [Indexed: 02/06/2023]
Abstract
AIMS To investigate the effects of the ginsenoside Rh2 on monospecies and multispecies cariogenic biofilms and explore the mechanism of the antibiofilm effect of Rh2 in vitro. METHODS AND RESULTS Streptococcus mutans, Streptococcus sobrinus and Streptococcus sanguinis were chosen to form the monospecies or multispecies biofilms. Crystal violet staining and laser scanning confocal microscopy were used to observe the effect of Rh2 on biofilms in vitro. Cytotoxicity was examined by the Cell Counting Kit-8. The effects of Rh2 on bacterial membranes were observed via transmission electron microscopy (TEM). The isobaric tags for relative and absolute quantification (iTRAQ) method were used to profile the common differentially expressed proteins. Gene expression was analysed by reverse transcription quantitative polymerase chain reaction. In general, the treatment of cariogenic biofilms with Rh2 significantly decreased biomass accumulation by inhibiting bacterial growth and extracellular polysaccharide synthesis without any cytotoxic effects. TEM imaging showed that Rh2 could disrupt the cell membranes of these bacteria. The iTRAQ results indicated that the levels of mannose-specific IIC/D and acetaldehyde/alcohol dehydrogenase were substantially down-regulated, while the mRNA expression of the corresponding genes were significantly changed. CONCLUSIONS Our data revealed a potential application for Rh2 in the protection against dental caries via the inhibition of cariogenic biofilms. SIGNIFICANCE AND IMPACT OF THE STUDY This study describes the first application of a ginsenoside against multispecies cariogenic biofilms. Rh2 may serve as an alternative agent to prevent dental caries by effectively modulating the pathogenic potentials of oral biofilms.
Collapse
Affiliation(s)
- X Cao
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, China
| | - Q Ye
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, China
| | - M Fan
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, China
| | - C Liu
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, China
| |
Collapse
|
45
|
Yin X, Archbold T, Burello N, Scolaro M, Li M, Wang W, Zhou K, Fan M. 363 Increased Intestinal Alkaline Phosphatase Maximal Activities Mediate Improvements in Growth and Gut Health Status in Weanling Pigs Fed the Antibiotic-Supplemented Diet. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- X Yin
- University of Guelph,Guelph, ON, Canada
| | | | - N Burello
- University of Guelph,Guelph, ON, Canada
| | - M Scolaro
- University of Guelph,Guelph, ON, Canada
| | - M Li
- Henan University of Animal Husbandry and Economy,China, Zhengshou, Henen, China
| | - W Wang
- University of Guelph,Guelph, ON, Canada
| | - K Zhou
- University of Guelph,Guelph, ON, Canada
| | - M Fan
- University of Guelph,Guelph, ON, Canada
| |
Collapse
|
46
|
Yin X, Wang W, Archbold T, Burello N, Scolaro M, Zhou K, Fan M. PSI-28 Genomic determinants of alkaline phosphatase catalytic affinity along the intestinal longitudinal axis of weanling pigs. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- X Yin
- University of Guelph,Guelph, ON, Canada
| | - W Wang
- University of Guelph,Guelph, ON, Canada
| | | | - N Burello
- University of Guelph,Guelph, ON, Canada
| | - M Scolaro
- University of Guelph,Guelph, ON, Canada
| | - K Zhou
- University of Guelph,Guelph, ON, Canada
| | - M Fan
- University of Guelph,Guelph, ON, Canada
| |
Collapse
|
47
|
Chen Y, Zhou L, Liao N, Gao P, Chen L, Li X, Fan M. Specific computed tomography imaging characteristics of congenital mesoblastic nephroma and correlation with ultrasound and pathology. J Pediatr Urol 2018; 14:571.e1-571.e6. [PMID: 30145031 DOI: 10.1016/j.jpurol.2018.07.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2018] [Accepted: 07/24/2018] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Congenital mesoblastic nephroma (CMN) is a common solid renal tumor in the neonate. Congenital mesoblastic nephroma can be divided into classic, cellular, and mixed types. The prognosis of CMN is very optimistic. But CMN can easily be misdiagnosed as the other malignant renal tumors by radiology. However, no studies have described the computed tomography (CT) imaging appearance of CNM in detail. The objective of this study is retrospective analyses of the multislice CT characteristics of CMN and their corresponding ultrasound findings and pathology. METHODS This retrospective study reviewed the enhanced CT images of the CMNs and other renal tumors in children younger than 1 year in the past 10 years from the First Affiliated Hospital of Sun Yat-sen University. Two radiologists had noted the CT imaging characteristics of these images. t-test and Fisher's exact test were used in the comparison of imaging characteristics between the CMNs and other renal tumors. RESULTS AND DISCUSSION Compared with other malignant renal tumors, the CMNs tend to appear as smaller round masses without clear coverage or clear boundary with the kidney in CT images (P < 0.01). The intratumor pelvis and the double-layer sign are the specific characteristics of CMNs (P < 0.01). The gender, quality of tumor (solid or solid-cystic), character of enhancement (homogeneous or heterogeneous enhancement), peri-renal hemorrhage, or peripheral lymph node enlargement showed no statistical significance (P > 0.05) between CMNs and other renal tumors. The appearances of CMN with classic components in the CT images are relevant to the pathological findings. The intratumor pelvis is caused by the classic components of CMN growing to encapsulate the pelvis. The double-layer sign in CT image correlates with the specific hypoechoic ring in ultrasound, which is caused by the slow blood flow and delay contrast agent filling in the blood sinus located in the peripheral part of the tumor. The differential diagnosis of CMN should include the other solitary renal tumors such as Wilms' tumor, clear-cell sarcoma of the kidney, and rhabdoid tumor of the kidney. CONCLUSION The unclear coverage and unclear boundary with the kidney, the intratumor pelvis, and double-layer sign after contrast were specific CT imaging characteristics of CMN.
Collapse
Affiliation(s)
- Y Chen
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58th, The Second Zhongshan Road, Guanzhou, China
| | - L Zhou
- Department of Ultrasound, The First Affiliated Hospital, Sun Yat-sen University, 58th, The Second Zhongshan Road, Guanzhou, China
| | - N Liao
- Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 58th, The Second Zhongshan Road, Guanzhou, China
| | - P Gao
- Department of Pediatric Surgery, The First Affiliated Hospital, Sun Yat-sen University, 58th, The Second Zhongshan Road, Guanzhou, China
| | - L Chen
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58th, The Second Zhongshan Road, Guanzhou, China
| | - X Li
- School of Public Health, Sun Yat-sen University, 58th, The Second Zhongshan Road, Guanzhou, China
| | - M Fan
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58th, The Second Zhongshan Road, Guanzhou, China.
| |
Collapse
|
48
|
Yang J, Fan M, Chen M, Pan L, Ma J, Lang J. Using Circulating Tumor DNA (ctDNA) As Screening and Predictive Marker in Cervical Carcinoma Patients Receiving Radiation Therapy. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
49
|
Xu X, Huang L, Chen J, Wang J, Wen J, Xie L, Liu D, Zhang J, Fan M. Application of Radiomics Signature Captured from Pretreatment CT to Predict Brain Metastases in Stage III/IV Non-small Cell Lung Cancer Patients with ALK Mutation. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Chen Y, Ye J, Zhu Z, Zhao W, Li L, Fan M, WU C, Tang H, Xu G, Lin Q, LI J, Xia Y, Yunhai L, Zhou J, Zhao K. Final Results of a Phase 3 Study of Comparing Paclitaxel Plus 5-Fluorouracil versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|